Erratum to: Current state of immunotherapy for non-small cell lung cancer [Transl Lung Cancer Res, 6, (2017)(196-211)] doi 10.21037/tlcr.2017.03.01

Research output: Contribution to journalComment/debatepeer-review

3 Scopus citations

Abstract

In the April 2017 issue of Translational Lung Cancer Research (TLCR), the review article "Current state of immunotherapy for non-small cell lung cancer" (1) was published with some errors. Borghaei et al. is labeled as CheckMate 17 instead of CheckMate 057 and conversely, Brahmer et al. is labeled as CheckMate 057 instead of CheckMate 017. Also in Tables 2 and 3, these two trials have been labeled in reverse. Also, the correct reference for CheckMate 021 (nivolumab in combination with chemotherapy arm) is reference number 23. The correct reference for CheckMate 021 (nivolumab and ipilimumab arm) is: Hellmann MD, Rizvi NA, Goldman JW, et al. Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. Lancet Oncol 2017;18:31-41. We are sorry for the inconvenience caused.

Original languageEnglish (US)
Pages (from-to)612
Number of pages1
JournalTranslational Lung Cancer Research
Volume6
Issue number5
DOIs
StatePublished - Oct 1 2017

All Science Journal Classification (ASJC) codes

  • Oncology

Fingerprint Dive into the research topics of 'Erratum to: Current state of immunotherapy for non-small cell lung cancer [Transl Lung Cancer Res, 6, (2017)(196-211)] doi 10.21037/tlcr.2017.03.01'. Together they form a unique fingerprint.

Cite this